Takeda signs a Co-Development Agreement with Molecular Templates for CD38-Targeted Engineered Toxin Bodies(ETBs) for Multiple Myeloma
Shots:
- Takeda will provide upfront of $30M and to pay royalties on commercialization. CD38-Targeted ETBs' development cost will be shared equally between both the parties
- Molecular Templates will receive development- regulatory and commercial milestone payments of up to $632.5M if company exercise its co-development option- or $337.5M if it does not exercise or opts out of its co-development option
- In Oct 2016- Takeda and Molecular signed agreement to develop CD38-targeted ETBs for oncology drug discovery programs
Ref: Molecular Templates | Image: Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com